Glycosmedia Weekly Diabetes News Update
View this email in your browser

Platinum Sponsors:

Boehringer Ingelheim Lilly

Gold Sponsors:

Novo Nordisk

AstraZeneca

Silver Sponsors:
 

Abbott Diabetes Care

Ericas

Glycosmedia Weekly Diabetes News - 08/07/2020

Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes

GAD65-specific immunotherapy has a significant effect on C-peptide retention in individuals with recent-onset type 1 diabetes who have the DR3-DQ2 haplotype (Diabetologia)


Examining if the relationship between BMI and incident type 2 diabetes among middle–older aged adults varies by race/ethnicity: evidence from the Multi‐Ethnic Study of Atherosclerosis (MESA)

This study supports including BMI and presence of type 2 diabetes risk factors as action points for clinicians to prioritize which adults aged ≥ 45 years should be screened (Diabetic Medicine)


Insights into the Role of Renal Biopsy in Patients with T2DM: A Literature Review of Global Renal Biopsy Results

We conclude that renal biopsy as early as possible is of great significance to enable personalized treatment to T2DM patients (Diabetes Therapy)


Bone mineral density spectrum in individuals with type 1 diabetes, LADA , and type 2 diabetes

BMD values in T1D, LADA and T2D were in an increasing order of mention. Patients with autoimmune diabetes were more susceptible to osteoporosis. A lower C‐peptide level may be responsible for decreased BMD in individuals with autoimmune diabetes (Diabetes/Metabolism Research and Reviews)


Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories – Insights from the EMPA‐REG OUTCOME trial

Empagliflozin may improve CV and kidney outcomes and slow progression of kidney disease in type 2 diabetes patients with DKD, irrespective of its clinical form, both with or without the presence of overt albuminuria (Diabetes, Obesity and Metabolism)


Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study

This study provides some genetic evidence that AMPK activation by metformin may protect against cardiovascular disease and cancer, which needs to be confirmed by randomised controlled trials (Diabetalogia)


Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study

URLi was compatible with insulin pump use with a safety profile similar to lispro (Diabetes Technology and Therapeutics)


Risk factors for hospitalization in youth with type 1 diabetes: Development and validation of a multivariable prediction model

Our multivariable prediction model identified patients at increased risk of admission in the 12 months following assessment (Pediatric Diabetes)


Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial

The increased mortality observed in the intensive glycemic control arm in the ACCORD trial is not likely to be explained by QT prolongation leading to lethal ventricular arrhythmias (Diabetes)


Share
Tweet
Forward
+1
Share
Please visit the Glycosmedia website for more features and information, including:

Journal Watch
Comment on recently published papers written by the medical editors of Glycosmedia.

Diabetes Updates
Updates written by Professor Steve Bain (Diabetologist) and Dr. Mark Freeman (Diabetologist).

Book and Product Reviews
A selection of book and product reviews written by the contributing editors of Glycosmedia.
The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Glycosmedia complies with the HONcode standard for trustworthy health information: verify here.


Copyright © 2020 Glycosmedia Partnership

Our mailing address is:
Glycosmedia
9 Woodburn Drive
West Cross
Swansea, West Glamorgan SA3 5TZ
United Kingdom

Add us to your address book


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp